8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 24, 2023

Commission File Number: 0-24260

LOGO

Amedisys, Inc.

(Exact name of registrant as specified in charter)

Delaware

11-3131700

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

AMED

The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 24, 2023, Amedisys, Inc. (the “Company”) appointed Allyson Guidroz, the Company’s Senior Vice President of Accounting, to serve as the Company’s Chief Accounting Officer and principal accounting officer for purposes of the rules and regulations of the Securities and Exchange Commission, effective immediately. In connection with Ms. Guidroz’s appointment, Scott G. Ginn will continue in his role as Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer and principal financial officer and will no longer serve as the Company’s principal accounting officer.

Ms. Guidroz has served as the Company’s Senior Vice President of Accounting since June 2018.

Ms. Guidroz will continue to participate in the Amedisys Holding, L.L.C. Amended and Restated Severance Plan for Presidents and Senior Vice Presidents.

Other than as set forth in this Current Report on Form 8-K, there are no arrangements or understandings between Ms. Guidroz and any other person pursuant to which Ms. Guidroz was appointed as Chief Accounting Officer or principal accounting officer. Ms. Guidroz does not have any family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer. There are no transactions in which Ms. Guidroz has an interest requiring disclosure under Item 404(a) of Regulation S-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


AMEDISYS, INC.

By:		/s/ Richard Ashworth
		Richard Ashworth President and Chief Executive Officer

DATE:		August 30, 2023

Amedisys Inc filed SEC Form 8-K: Leadership Update